{
    "clinical_study": {
        "@rank": "10183", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop\n      tumor cells from dividing so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of ixabepilone in treating patients who\n      have relapsed and/or refractory stage III or stage IV ovarian epithelial cancer or primary\n      peritoneal cancer."
        }, 
        "brief_title": "Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer", 
        "condition": [
            "Ovarian Cancer", 
            "Peritoneal Cavity Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Peritoneal Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      Primary\n\n        -  Determine the antitumor activity of ixabepilone, in terms of clinical response and\n           progression-free survival, in patients with relapsed and/or refractory stage III or IV\n           ovarian epithelial or primary peritoneal cancer.\n\n        -  Determine the nature and degree of toxicity of this drug in these patients.\n\n      Secondary\n\n        -  Correlate pre-ixabepilone survivin mRNA and protein levels in patient-derived ovarian\n           cancer cells with quality of response (i.e., at least partial response vs no response).\n\n        -  Correlate CYP3A4 (3A4*1B), 3A5 (3A5*1), and 3A7 (ER6 p variation) allelic polymorphisms\n           with parent drug kinetic parameters, toxicity, and efficacy of this drug in these\n           patients.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive ixabepilone IV over 1 hour once weekly on weeks 1-3. Treatment repeats\n      every 4 weeks for a total of 3 courses in the absence of disease progression or unacceptable\n      toxicity.\n\n      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 12\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed stage III or IV ovarian epithelial cancer\n             or primary peritoneal carcinoma\n\n               -  Recurrent or refractory disease\n\n                    -  Previously treated with 1, and only 1, prior chemotherapy regimen\n                       containing carboplatin, cisplatin, or another organoplatinum compound and\n                       paclitaxel or docetaxel\n\n                    -  Initial treatment may include high-dose, consolidation, or extended therapy\n                       administered after surgical or non-surgical assessment\n\n          -  Bidimensionally measurable disease by physical exam, CT scan, or MRI\n\n               -  Ascites and pleural effusions are not measurable disease\n\n               -  No prior irradiation to indicator lesions\n\n        PATIENT CHARACTERISTICS:\n\n        Age\n\n          -  18 to 75\n\n        Performance status\n\n          -  GOG 0-2\n\n        Life expectancy\n\n          -  Not specified\n\n        Hematopoietic\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  No prior bleeding disorder or unexplained bleeding\n\n        Hepatic\n\n          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n\n          -  SGOT/SGPT no greater than 2.5 times ULN\n\n          -  Alkaline phosphatase no greater than 2.5 times ULN\n\n        Renal\n\n          -  Creatinine no greater than 1.5 times ULN\n\n        Other\n\n          -  No active infection requiring antibiotics\n\n          -  No grade 2 or greater neuropathy (sensory and motor)\n\n          -  No other malignancy within the past 5 years except nonmelanoma skin cancer\n\n          -  No prior recurrent grade 2 or greater hypersensitivity reactions to Cremophor EL,\n             docetaxel, or paclitaxel\n\n          -  No other medical condition that would preclude study participation\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy\n\n          -  At least 3 weeks since prior biologic or immunologic therapy for ovarian epithelial\n             or primary peritoneal carcinoma\n\n        Chemotherapy\n\n          -  See Disease Characteristics\n\n          -  At least 3 weeks since prior chemotherapy and recovered\n\n          -  No prior ixabepilone\n\n          -  No prior cytotoxic chemotherapy (including retreatment with initial chemotherapy\n             regimens) for recurrent or persistent ovarian epithelial or primary peritoneal\n             carcinoma\n\n        Endocrine therapy\n\n          -  At least 1 week since prior hormonal therapy for ovarian epithelial or primary\n             peritoneal carcinoma\n\n          -  Concurrent hormonal replacement therapy allowed\n\n        Radiotherapy\n\n          -  See Disease Characteristics\n\n          -  At least 3 weeks since prior radiotherapy and recovered\n\n          -  No prior radiotherapy to a site of measurable disease used on study\n\n          -  No prior radiotherapy to more than 25% of bone marrow\n\n        Surgery\n\n          -  See Disease Characteristics\n\n          -  Recovered from prior surgery\n\n        Other\n\n          -  At least 3 weeks since other prior therapies for ovarian epithelial or primary\n             peritoneal carcinoma\n\n          -  No prior cancer treatment for other invasive malignancies that would preclude study\n             participation\n\n          -  No concurrent heparin or other anticoagulants\n\n          -  No concurrent Hypericum perforatum (St. John's wort) or any product containing this\n             compound"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "February 14, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00030706", 
            "org_study_id": "CDR0000069190", 
            "secondary_id": [
                "AECM-3632", 
                "MCC-12602", 
                "NCI-3632"
            ]
        }, 
        "intervention": {
            "intervention_name": "ixabepilone", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "stage III ovarian epithelial cancer", 
            "stage IV ovarian epithelial cancer", 
            "recurrent ovarian epithelial cancer", 
            "peritoneal cavity cancer"
        ], 
        "lastchanged_date": "July 23, 2008", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/AECM-3632"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bronx", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10461"
                }, 
                "name": "Albert Einstein Cancer Center at Albert Einstein College of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study Of Epothilone B Analogue BMS-247550 In Relapse And/Or Refractory Stage III Or IV Ovarian Epithelial Cancer, Following Front-Line Treatment With Platinum Plus Taxane-Based Chemotherapy", 
        "overall_official": {
            "affiliation": "Albert Einstein College of Medicine of Yeshiva University", 
            "last_name": "Gary L. Goldberg, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": {
            "measure": "Incidence of clinical remission", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00030706"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Albert Einstein College of Medicine of Yeshiva University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2004", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2006"
    }, 
    "geocoordinates": {
        "Albert Einstein Cancer Center at Albert Einstein College of Medicine": "40.85 -73.867"
    }
}